The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A randomized, open-label, 2-period, crossover pharmacokinetic study to evaluate, after single and multiple doses, whether esomeprazole magnesium (Nexium) 40 mg opened capsule in water, administered through a nasogastric tube, is bioequivalent to an intact 40 mg capsule, administered orally, in healthy subjects
- collapse A single-centre, open, two-way cross-over, comparative study of esomeprazole 20 mg once daily and rabeprazole 10 mg once daily regarding 24-hour intragastric pH following single and repeated oral administration in healthy male and female subjects
- collapse A single-centre, open, two-way cross-over, comparative study of esomeprazole 40 mg once daily and lansoprazole 30 mg once daily regarding 24-hour intragastric pH following single and repeated oral administration in patients with symptoms of GERD
- collapse A Comparative Efficy Studie of Esomeprazole Magnesium (40 mg qd) and Lansoprazole (30 mg qd) in Patients with Erosive Esophagitis - EAZEE
- collapse CHEER
- collapse A randomized, single-center, open-label, two-period cross-over, pharmacokinetic study, to evaluate the bioequivalence of a single 40 mg H 199/18 dose administered as an intact capsule and as an open capsule in healthy male and female volunteers.
- collapse Maintenance treatment of patients with healed reflux esophagitis, comparing remission rates during 6 months with esomeprazole 20 mg q.d. and lansoprazole 15 mg q.d. - A randomised, double-blind multi-centre study - METROPOLE
- collapse A comparative study on 40 mg H 199/18 and 40 mg omeprazole with regard to effect on 24-hour intragastric pH in healthy subjects
- collapse A comparative study on 40 mg H 199/18 and 30 mg lansoprazole with regard to effect on 24-hour intragastric pH in healthy subjects
- collapse A comparative study on 40 mg H 199/18 and 40 mg pantoprazole with regard to effect on 24-hour intragastric pH in patients with symptomatic gastroesophageal reflux disease
